Avalyn Pharma (AVLN) Stock Price, News & Analysis

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines for serious, rare respiratory diseases. The company focuses on pulmonary fibrosis and other interstitial lung diseases, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Its common stock is listed on the Nasdaq Global Select Market under the ticker symbol AVLN.

Avalyn's pipeline is built around inhaled formulations of established antifibrotic drug classes. Its lead programs include AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled formulation of nintedanib. The company is developing these candidates for pulmonary fibrosis indications where treatment is directed at lung tissue affected by progressive scarring and impaired respiratory function.

The company's development model centers on targeted delivery of antifibrotic therapy through inhalation. Avalyn's research activities include clinical studies, quantitative lung imaging, patient-reported quality-of-life measures, supportive care research, and work on how patients and caregivers experience inhaled treatment. Company news has also described the use of high-resolution computed tomography imaging in AP01 research and the evaluation of AP01 delivery and supportive care experiences in pulmonary fibrosis.

Avalyn reports one operating and reportable segment: the business of developing and commercializing targeted therapies for rare lung diseases. As a clinical-stage biopharmaceutical company, its operating activities are concentrated on drug development, clinical program execution, product development, medical research, and preparations associated with potential commercialization of respiratory therapies.

Avalyn became a Nasdaq-listed public company following the closing of its initial public offering of common stock. Its public-company profile includes capital-structure matters related to its listed shares, governance updates related to its board and leadership structure, and operating updates tied to its AP01 and AP02 programs.